AstraZeneca (AZN) Earnings Date & Reports
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999... Show more
AZN is expected to report earnings to fall 3.10% to $2.50 per share on July 27
AstraZeneca (AZN) Q1 2026 Earnings Recap: Oncology Fuels Revenue Beat
Key Takeaways
- Total revenue grew 8% at constant exchange rates (CER) to $15.3 billion, topping consensus estimates of around $14.9-15.0 billion.
- Core earnings per share (EPS) rose 5% to $2.58, exceeding expectations of $2.52-$2.55.
- Oncology product sales surged 16% at CER, driven by Enhertu, Imfinzi, and Lynparza.
- Rare Disease revenue increased 15% at CER, supporting overall growth.
- Company maintained full-year 2026 guidance for mid-to-high single-digit revenue growth and low double-digit core EPS growth at CER.
- Shares dipped about 2% post-earnings amid broader market pressures and U.S. pricing concerns.
Earnings Context and Why It Matters
AstraZeneca's Q1 2026 earnings provide critical insights into the pharmaceutical giant's execution amid a competitive oncology landscape and evolving regulatory pressures. As a leader in cancer treatments and rare diseases, the company has transformed through blockbuster drugs like Tagrisso and Farxiga (dapagliflozin). Recent quarters showed steady growth, but investors watch for pipeline momentum and margin expansion. This report matters as it validates progress toward 2030 ambitions, signals demand for key franchises, and addresses U.S. drug pricing risks that could impact global launches. With 21 new molecular entities (NMEs) in late-stage development, strong results reinforce AstraZeneca's position in high-growth areas.
AstraZeneca reported total revenue of $15,288 million in Q1 2026, up 8% at CER (13% reported) from $13,500 million prior year, beating consensus around $14.9 billion. Product sales reached $14,386 million (+7% CER), with alliance revenue at $825 million (+26% CER). Oncology drove growth at 16% CER, led by Enhertu (+13%), Imfinzi (+24%), and Lynparza (+11%). Rare Disease grew 15% CER, while Cardiovascular, Renal & Metabolism (CVRM) rose 15% CER on Farxiga (+18%). Respiratory & Immunology (R&I) increased 15% CER, boosted by Breztri (+18%).
Core operating profit climbed 12% CER to $5,352 million, with core EPS at $2.58 (+5% CER), above estimates; reported EPS was $1.99 (+8% CER). Guidance for FY 2026 remains unchanged: mid-to-high single-digit total revenue growth and low double-digit core EPS growth at CER, with core tax rate 18-22%.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.
Market Reaction and Investor Sentiment
AstraZeneca shares fell approximately 2% on April 29 following the earnings release, despite beats on revenue and EPS. The dip occurred amid broader market weakness and investor concerns over potential U.S. drug pricing reforms impacting future launches. Sentiment remains positive on pipeline progress, with analysts noting robust oncology demand as a key driver. Pre-earnings, expectations were high given prior trends, but the reaction highlights sensitivity to macro factors.
Forward Outlook and Key Factors to Monitor
AstraZeneca reaffirmed its FY 2026 guidance, signaling confidence in sustained growth. Investors should track execution against mid-to-high single-digit revenue growth and low double-digit core EPS expansion at CER. Oncology remains pivotal, with upcoming readouts like DESTINY trials for Enhertu expansions and Imfinzi combinations.
Pipeline catalysts include Phase III data for tozorakimab in chronic obstructive pulmonary disease (COPD) and efzimfotase alfa in hypophosphatasia. Recent approvals—14 since Q4 2025—bolster the launch portfolio. Recent deals, like the $1.2 billion CSPC collaboration for obesity therapies, add long-term potential but increase R&D spend.
U.S. pricing pressures pose risks, as noted by management. Monitor demand for blockbusters like Farxiga amid competition, margin trends with R&D at 23% of revenue, and foreign exchange impacts. Next results on July 27 for H1/Q2 2026 will provide updates. Overall, positive Phase III momentum supports the 2030 ambition of $80 billion peak sales from new medicines.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor